⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SYRE News
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
globenewswire.com
SYRE
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
globenewswire.com
SYRE
Spyre Therapeutics Announces Grants of Inducement Awards
globenewswire.com
SYRE
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com
SYRE
Form 8-K
sec.gov
SYRE